Eruptive nevi and hair depigmentation related to regorafenib

European Journal of Dermatology

Volumn 25, Issue 1, 2015, Pages 85-86

  Sibaud, Vincent ^a   Munsch, Coline ^a   Lamant, Laurence ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; REGORAFENIB; CARBANILAMIDE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ARTICLE; CASE REPORT; DEPIGMENTATION; FOLLOW UP; HAIR DEPIGMENTATION; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; INFLAMMATION; MALE; MELANOCYTIC NEVUS; METASTATIC COLORECTAL CANCER; MIDDLE AGED; SKIN MANIFESTATION; CHEMICALLY INDUCED; COLORECTAL NEOPLASMS; DRUG EFFECTS; HAIR COLOR; NEVUS; PATHOLOGY; SKIN TUMOR;

COLORECTAL NEOPLASMS; HAIR COLOR; HUMANS; MALE; MIDDLE AGED; NEVUS, INTRADERMAL; PHENYLUREA COMPOUNDS; PYRIDINES; SKIN NEOPLASMS;

EID: 84955691496     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2014.2462     Document Type: Article

References (10)

1. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 303-12.
2. Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 295302.
3. De Wit M, Boers-Doets CB, Saettini A, et al. Prevention and management of adverse events related to regorafenib. Support Care Cancer 2014; 22: 837-46.
4. Belum VR, Wu S, Lacouture ME. Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. Invest New Drugs 2013; 31: 1078-86.
5. Kong HH, Sibaud V, Chanco Turner ML, et al. Sorafenib-induced eruptive melanocytic lesions. Arch Dermatol 2008; 144: 820-2.
6. Boussemart L, Routier E, Mateus C, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol 2013; 24: 1691-7.
7. Anforth R, Blumetti TC, Kefford RF, et al. Manifestations of dabrafenib (GSK2118436): A selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol 2012; 167: 115360.
8. Zimmer L, Hillen U, Livingstone E, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 2012; 30: 2375-83.
9. Perier-Muzet M, Thomas L, Poulalhon N, et al. Melanoma Patients under Vemurafenib: Prospective Follow-Up of Melanocytic Lesions by Digital Dermoscopy. J Invest Dermatol 2014; 134: 1351-8.
10. Robert C, Sibaud V, Mateus C, et al. Advances in the management of cutaneous toxicities of targeted therapies. Semin Oncol 2012; 39: 227-40.